Must Trial | search
Click here to view Must Trial news from 60+ newspapers.
Bookmark or Share- MUST Trial - Uveitis.org | OIUFThe MUST trial is a randomized controlled clinical trial comparing two treatments for patients with vision-threatening non-infectious intermediate uveitis, posterior uveitis, or panuveitis: local therapy with fluocinolone acetonide intraocular implant in affected eyes; versus standard therapy: systemic corticosteroid therapy supplemented, when ...
- The Fluocinolone Implant and Posterior UveitisBy Debra A. Goldstein, MD. Add to My Bookmarks. Comments. Views 163. The fluocinolone implant, Retisert, is the first U.S. Food and Drug Administration (FDA) approved treatment for non-infectious intermediate, posterior, or panuveitis.
- THE MULTICENTER UVEITIS STEROID TREATMENT (MUST) TRIALThe MUST trial was designed as a 2-year randomized clinical trial, followed by a nonprespecified longitudinal follow-up of the trial cohort.1. Objective: To compare RETISERT versus systemic therapy in the treatment of long-term vision and other outcomes in patients with uveitis1.
- The Multicenter Uveitis Steroid Treatment Trial: Rationale, Design, and ...The Multicenter Uveitis Steroid Treatment (MUST) trial is a randomized, partially masked, comparative multicenter clinical trial comparing the effectiveness and safety of local therapy with the fluocinolone acetonide implant (Bausch & Lomb, Inc) versus systemic therapy with oral corticosteroids and immunosuppressive drugs when indicated 22 for ...
- Electrophysiologic Testing to Identify Patients with Coronary Artery ...The primary objective of the Multicenter Unsustained Tachycardia Trial was to evaluate the efficacy of antiarrhythmic therapy guided by electrophysiologic testing in reducing the risk of sudden...
More
